reviva pharmaceuticals holdings inc - RVPH
RVPH
Close Chg Chg %
0.80 -0.44 -55.73%
Open Market
0.35
-0.44 (55.73%)
Volume: 13.17M
Last Updated:
May 13, 2026, 4:00 PM EDT
Company Overview: reviva pharmaceuticals holdings inc - RVPH
RVPH Key Data
| Open $0.36 | Day Range 0.26 - 0.44 |
| 52 Week Range 0.26 - 23.20 | Market Cap $7.56M |
| Shares Outstanding 12.81M | Public Float 12.56M |
| Beta 0.56 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$4.56 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 966.03K |
RVPH Performance
No Data Available
RVPH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Reviva Pharmaceuticals Holdings Inc - RVPH
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | - | - | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | - | - |
Depreciation
| - | - | - | - | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | - | - |
Gross Income
| - | - | - | - | - |
Gross Income Growth
| - | - | - | - | - |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 24.31M | 39.50M | 30.80M | 20.20M | |
Research & Development
| 18.95M | 31.42M | 22.91M | 11.71M | |
Other SG&A
| 5.36M | 8.08M | 7.89M | 8.49M | |
SGA Growth
| +140.55% | +62.52% | -22.04% | -34.41% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 194.71K | 239.22K | (717.64K) | (89.01K) | |
EBIT after Unusual Expense
| (24.50M) | (39.74M) | (30.08M) | (20.11M) | |
Non Operating Income/Expense
| 182.80K | 498.96K | 200.45K | 278.41K | |
Non-Operating Interest Income
| - | - | 361.37K | 311.37K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 18.50K | 13.40K | - |
Interest Expense Growth
| - | - | - | -27.55% | - |
Gross Interest Expense
| - | - | 18.50K | 13.40K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (24.32M) | (39.24M) | (29.90M) | (19.85M) | |
Pretax Income Growth
| -185.57% | -61.37% | +23.81% | +33.62% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| 20.78K | 16.95K | 19.51K | 18.89K | |
Income Tax - Current - Domestic
| 9.00K | 2.40K | 2.10K | 9.04K | |
Income Tax - Current - Foreign
| 11.78K | 14.55K | 17.41K | 9.85K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (24.34M) | (39.26M) | (29.92M) | (19.86M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (24.34M) | (39.26M) | (29.92M) | (19.86M) | |
Net Income Growth
| -185.61% | -61.31% | +23.79% | +33.60% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (24.34M) | (39.26M) | (29.92M) | (19.86M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (24.34M) | (39.26M) | (29.92M) | (19.86M) | |
EPS (Basic)
| -24.9422 | -32.9948 | -18.052 | -5.4756 | |
EPS (Basic) Growth
| -116.45% | -32.29% | +45.29% | +69.67% | |
Basic Shares Outstanding
| 975.82K | 1.19M | 1.66M | 3.63M | |
EPS (Diluted)
| -24.9422 | -32.9948 | -18.052 | -5.4756 | |
EPS (Diluted) Growth
| -116.45% | -32.29% | +45.29% | +69.67% | |
Diluted Shares Outstanding
| 975.82K | 1.19M | 1.66M | 3.63M | |
EBITDA
| (24.31M) | (39.50M) | (30.80M) | (20.20M) | |
EBITDA Growth
| -140.55% | -62.52% | +22.04% | +34.41% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 18.50 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.385 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -1.78 | |
| Last Quarter’s Earnings | -0.46 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -5.48 | Next Fiscal Year Estimate | -1.67 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 2 | 2 |
| Mean Estimate | -0.39 | -0.46 | -1.78 | -1.67 |
| High Estimates | -0.36 | -0.36 | -1.60 | -1.44 |
| Low Estimate | -0.41 | -0.55 | -1.96 | -1.90 |
| Coefficient of Variance | -9.18 | -29.53 | -14.30 | -19.48 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Reviva Pharmaceuticals Holdings Inc - RVPH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
An error occurred while fetching the data.